Department of Urology, Peking University First Hospital, Beijing, China.
The Institution of Urology, Peking University, Beijing, China.
Front Immunol. 2023 Aug 24;14:1212476. doi: 10.3389/fimmu.2023.1212476. eCollection 2023.
Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immunomodulatory role in tumor microenvironment (TME) which is closely related to immune escape of tumor cells, thus influence tumor progress. Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise. In this review, we will summarize the recent research advances in tumor immunotherapy, including the molecular mechanisms and clinical effects as well as limitations of immunotherapy.
免疫疗法开创了癌症治疗的新时代，癌症免疫疗法持续焕发生机。癌症免疫疗法的临床目标是激活宿主免疫系统，为恶性肿瘤提供被动或主动免疫。肿瘤浸润白细胞（TILs）在肿瘤微环境（TME）中发挥免疫调节作用，与肿瘤细胞的免疫逃逸密切相关，从而影响肿瘤的进展。几种癌症免疫疗法，包括免疫检查点抑制剂（ICIs）、癌症疫苗、过继细胞转移（ACT），已显示出巨大的疗效和潜力。在这篇综述中，我们将总结肿瘤免疫治疗的最新研究进展，包括免疫疗法的分子机制、临床效果和局限性。
